WINTON GROUP Ltd Sells 73,816 Shares of Henry Schein, Inc. $HSIC

WINTON GROUP Ltd lessened its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 64.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 40,366 shares of the company’s stock after selling 73,816 shares during the quarter. WINTON GROUP Ltd’s holdings in Henry Schein were worth $3,051,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Ameriprise Financial Inc. grew its holdings in shares of Henry Schein by 3,275.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after purchasing an additional 2,199,695 shares during the last quarter. Norges Bank bought a new stake in shares of Henry Schein in the 4th quarter worth about $88,116,000. Bank of America Corp DE grew its holdings in shares of Henry Schein by 204.2% in the 2nd quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock worth $72,712,000 after purchasing an additional 668,182 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Henry Schein by 171.9% in the 4th quarter. SG Americas Securities LLC now owns 820,698 shares of the company’s stock worth $62,028,000 after purchasing an additional 518,914 shares during the last quarter. Finally, Artisan Partners Limited Partnership grew its holdings in shares of Henry Schein by 5.7% in the 3rd quarter. Artisan Partners Limited Partnership now owns 6,833,041 shares of the company’s stock worth $453,509,000 after purchasing an additional 370,837 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.

Henry Schein Price Performance

Shares of NASDAQ HSIC opened at $77.45 on Monday. The firm’s 50-day simple moving average is $74.70 and its 200 day simple moving average is $75.96. The company has a market cap of $8.82 billion, a price-to-earnings ratio of 23.40, a price-to-earnings-growth ratio of 1.49 and a beta of 0.82. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59. Henry Schein, Inc. has a 12-month low of $61.94 and a 12-month high of $89.29.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.12. The business had revenue of $3.37 billion for the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The firm’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, research analysts expect that Henry Schein, Inc. will post 5.32 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Wells Fargo & Company upped their target price on shares of Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. Mizuho lowered their target price on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Barrington Research set a $97.00 target price on shares of Henry Schein and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Morgan Stanley reaffirmed an “underweight” rating and issued a $64.00 target price (up from $61.00) on shares of Henry Schein in a report on Friday, April 24th. Finally, Citigroup assumed coverage on shares of Henry Schein in a report on Wednesday, April 15th. They issued a “buy” rating and a $100.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Henry Schein currently has a consensus rating of “Hold” and a consensus target price of $86.83.

Insider Buying and Selling

In related news, Director Kurt P. Kuehn sold 2,844 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $78.96, for a total transaction of $224,562.24. Following the transaction, the director owned 15,420 shares in the company, valued at $1,217,563.20. This represents a 15.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Thomas C. Popeck sold 1,355 shares of the company’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $72.79, for a total transaction of $98,630.45. Following the transaction, the chief executive officer owned 86,182 shares in the company, valued at approximately $6,273,187.78. This trade represents a 1.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.89% of the stock is owned by corporate insiders.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.